Success Story: Overcoming RFE to Achieve I-140 EB1A Approval for a Cell Biology Researcher
Client’s Testimonial:
"I appreciate your help in the process of RFE preparation and submission.”
On May 4th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Scientist in the Field of Cell Biology (Approval Notice).
General Field: Cell Biology
Position at the Time of Case Filing: Research Scientist
Country of Origin: China
State of Residence at the Time of Filing: Texas
Approval Notice Date: May 4th, 2026
Processing Time: 32 months, 5 days (Premium Processing Upgrade Requested)
Case Summary:
We are pleased to share that North America Immigration Law Group successfully secured I-140 EB1A approval for a cell biology researcher with a Ph.D. in cell biology. Although the case received a Request for Evidence, the petition was ultimately approved after presenting a focused record of extraordinary ability, sustained influence, and continued benefit to the United States.
The client’s research centers on calcium signaling regulation in cell biology, with particular emphasis on esophageal cancer treatment, targeted nanoparticles, store-operated calcium channels, intracellular signaling pathways, and related esophageal conditions. At the time of filing, the client was working as a research scientist, continuing research on targeted nanoparticles for esophageal cancer treatment, store-operated calcium channels in esophageal cancer, and intracellular calcium signaling in eosinophilic esophagitis.
The petition emphasized that the client’s record was not simply a collection of academic achievements, but a pattern of recognized influence. The client had authored 19 peer-reviewed scientific articles, and the work had been cited 317 times by other researchers. Rather than presenting these numbers as self-evident, we explained how the citation record showed independent reliance on the client’s findings, especially in studies involving smart nanoregulators, calcium signaling, organoid systems, and therapeutic approaches for esophageal conditions.
We also highlighted the client’s peer-review service. The client had completed at least 11 reviews for scholarly journals, which helped demonstrate that journal editors relied on the client’s expertise to evaluate the work of other researchers. In the EB1A framework, this evidence supported not only the judging criterion, but also the broader final merits argument that the client had earned peer trust within the field.
The petition further addressed the major significance of the client’s original contributions by showing how the client’s work advanced targeted nanoparticle systems for esophageal cancer treatment, novel approaches involving calcium signaling inhibitors, and research into cellular mechanisms relevant to esophageal conditions. We also incorporated evidence that the client’s research had been connected to major funding sources, as additional objective support for the importance and practical relevance of the work.
Four recommendation letters were submitted in support of the petition. These letters helped connect the objective evidence to the EB1A legal standard by explaining why the client’s findings were viewed as important by other experts in the field, how independent researchers had used the client’s work, and why the client’s continued research would benefit the United States.
“Given the impact of [Client’s] research, her continued work is unquestionably critical to improving the cell biology field and to public health in the United States and around the world.”
Despite the RFE, the case was approved. This approval reflects the strength of a carefully prepared EB1A petition that framed the client’s publications, citations, peer-review activity, funded research record, and expert support as evidence of sustained acclaim and major scientific significance in cell biology. Congratulations to the client on this important achievement.